Trump Taps Heidi Overton to Lead FDA Amid Agency Turmoil and Policy Shifts

President Donald Trump is set to nominate White House policy aide Dr. Heidi Overton as the next Commissioner of the Food and Drug Administration (FDA), a move reported on August 18, 2026, that signals a new chapter for the agency after a period of significant upheaval. Overton, currently the Deputy Director of the White House Domestic Policy Council, will step into a role that has seen considerable turmoil following the recent resignation of her predecessor, Marty Makary. This appointment comes as the FDA grapples with over 3,000 staff departures and concerns about political influence impacting regulatory decisions, particularly after Makary's 13-month tenure was marked by controversy over issues like vaccine policy and abortion medication. Overton's background as a board-certified physician with a PhD in clinical investigation, coupled with her work at the conservative America First Policy Institute, positions her to potentially steer the agency toward policies aligning with the administration's broader health agenda, including a focus on drug pricing and a recent executive order addressing childhood vaccine schedule. Her nomination, which awaits Senate confirmation, will be closely watched by the pharmaceutical industry, public health advocates, and international partners. Overton's lack of direct experience in food policy or managing a large regulatory body like the FDA has raised questions, and her past advocacy for changes to vaccine recommendations and her strong stance on reproductive health issues suggest potential shifts in the agency's direction. This critical leadership change could redefine the FDA regulatory landscape for years to come, impacting everything from drug approvals to food safety standards.